References

Connolly MP, Kotsopoulos N, Ustianowski A. Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C. J Med Econ. 2018; 21:(1)19-26 https://doi.org/10.1080/13696998.2017.1371032

Cooper CM, Godlewska B, Sharpley AL, Barnes E, Cowen PJ, Harmer CJ. Interferon-α induces negative biases in emotional processing in patients with hepatitis C virus infection: a preliminary study. Psychol Med. 2018; 48:(6)998-1007 https://doi.org/10.1017/S0033291717002379

DeSteno D, Gross JJ, Kubzansky L. Affective science and health: the importance of emotion and emotion regulation. Health Psychol. 2013; 32:(5)474-486 https://doi.org/10.1037/a0030259

Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open. 2013; 3:(1) https://doi.org/10.1136/bmjopen-2012-001570

Frederickson BL. The role of positive emotions in positive psychology: the broaden-and-build theory of positive emotions. Am Psychol. 2001; 56:(3)218-226 https://doi.org/10.1037/0003-066X.56.3.218

Frederickson BL, Joiner T. Reflections on positive emotions and upward spirals. Am Psycho. 2018; 13:(2)194-199 https://doi.org/10.1177/1745691617692106

Gianaros PJ, Marsland AL, Kuan DC-H An inflammatory pathway links atherosclerotic cardiovascular disease risk to neural activity evoked by the cognitive regulation of emotions. Biol Psychiatry. 2014; 75:(9)738-745 https://doi.org/10.1016/j.biopsych.2013.10.012

Hopwood CJ, Schade N, Matusiewicz A, Daughters SB, Lejuez CW. Emotion regulation promotes persistence in a residential substance abuse treatment. Subst Use Misuse. 2015; 50:(2)251-256 https://doi.org/10.3109/10826084.2014.977393

Kunzmann U, Wrosch C. Comment: the emotion-health link: perspectives from a lifespan theory of discrete emotions. Emot Rev. 2018; 10:(1)59-61 https://doi.org/10.1177/1754073917719332

Mann M, Hosman CMH, SchaalmaNanne HP, de Vries K. Self-esteem in a broad-spectrum approach for mental health promotion. Health Educ Res. 2004; 19:(4)357-372 https://doi.org/10.1093/her/cyg041

McColl-Kennedy JR, Danaher TS, Gallan AS, Orsingher C, Lervik-Olsen L, Verma R. How do you feel today? Managing patient emotions during health care experiences to enhance wellbeing. J Bus Res. 2017; 79:247-259 https://doi.org/10.1016/j.jbusres.2017.03.022

Mehta G, Dusheiko G. Hepatitis C treatment and quality of life—you can't always get what you want, but you might get what you need. J Hepatol. 2015; 63:300-302 https://doi.org/10.1016/j.jhep.2015.05.004

Polis S, Zang L, Mainali B, Pons R, Pavendranathan G, Zekry A, Fernandes R. Factors associated with medication adherence in patients living with cirrhosis. J Clin Nurs. 2016; 25:(1–2)204-212 https://doi.org/10.1111/jocn.13083

Stam K, Sieben I, Verbakel E, De Graaf PM. Employment status and subjective wellbeing: the role of the social norm to work. Work Employ Soc. 2016; 30:(2)309-333 https://doi.org/10.1177/0950017014564602

Tompkins CNE, Wright NMJ, Jones L. Impact of a positive hepatitis C diagnosis on homeless injecting drug users: a qualitative study. Br J Gen Pract. 2005; 55:(513)263-268

Treloar C, Rhodes T. The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis. Qual Health Res. 2009; 19:(9)1321-1334 https://doi.org/10.1177/1049732309341656

Weiss NH, Sullivan TP, Tull MT. Explicating the role of emotion dysregulation in risky behaviors: A review and synthesis of the literature with directions for future research and clinical practice. Curr Opin Psychol. 2015; 3:22-29 https://doi.org/10.1016/j.copsyc.2015.01.013

World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Advocacy brief. 2016. https://tinyurl.com/y47nwmfzf (accessed 28 June 2019)

Yarlott L, Heald E, Forton D. Hepatitis C virus infection, and neurological and psychiatric disorders—a review. J Adv Res. 2017; 8:139-148 https://doi.org/10.1016/j.jare.2016.09.005

Yeoh SW, Holmes CAN, Saling MM, Everall IP, Nicoll AJ. Depression, fatigue and neurocognitive deficits in chronic hepatitis C. Hepatol Int. 2018; 12:(4)294-304 https://doi.org/10.1007/s12072-018-9879-5

Younossi ZM, Stepanova M, Afdal N Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015; 63:(2)337-345 https://doi.org/10.1016/j.jhep.2015.03.014

Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol. 2016; 111:(6)808-816 https://doi.org/10.1038/ajg.2016.99

Younossi ZM, Stepanova M, Gordon S Patient-reported outcomes following treatment of chronic hepatitis C virus infection with sofosbuvir and velpatasvir, with or without voxilaprevir. Clin Gastroenterol Hepatol. 2018; 16:(4)567-574 https://doi.org/10.1016/j.cgh.2017.11.023

Exploring the emotions of patients undergoing therapy for hepatitis C

11 July 2019
Volume 28 · Issue 13

Abstract

Background:

direct-acting antiviral (DAA) therapy is highly efficacious in the treatment of hepatitis C (HCV). The literature to date has focused primarily on the physical health benefits of viral eradication.

Aims:

this study explored patient emotions during and after DAA therapy for HCV.

Methods:

over a 6-month period, 178 patients attending a viral hepatitis clinic for treatment of HCV were posed a single question: ‘How do you feel about your diagnosis of hepatitis C today?’ Responses were transcribed verbatim, thematically coded and visualised using WordArt software.

Findings:

the images depict the evolution of patients' perceptions of HCV before, during and after DAA therapy. Responses before treatment were predominantly negative, often describing the fear of contagion and feelings of isolation, secrecy and loneliness. After treatment, patients often described feeling positive and more motivated.

Conclusions:

the results demonstrate that treatment of HCV has a transformative effect on patients' perception of the impact of HCV on their wellbeing. This may promote a more positive outlook and, in turn, facilitate patient engagement with healthcare.

Direct-acting antiviral (DAA) therapy has revolutionised the treatment of hepatitis C (HCV). Current treatment regimens are highly efficacious, with almost all patients receiving DAA therapy achieving a sustained virologic response (SVR) or ‘cure’. The literature to date has focused primarily on the physical health benefits of viral eradication and lacks qualitative assessments of the impact of HCV on patients' mental wellbeing or emotional states. Recent studies have demonstrated significant improvements in patient-reported outcomes (PROs) following the achievement of SVR.

Many papers have qualitatively explored the impact of receiving an HCV diagnosis during the era of interferon therapy (Tompkins et al, 2005; Treloar and Rhodes, 2009). At that time, understanding a patient's emotional state and mental health was crucial to assess their suitability to receive treatment, as interferon could trigger the onset of depression (Cooper et al, 2018).

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content